Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood

Inclusion Criteria: * Confirmed diagnosis of breast, colon or prostate cancer * No prior cancer therapy or failed first line therapy * \>= 25 CTC per 7.5 mL of blood within 1 week prior to oncopheresis treatment * \> 1 month life expectancy * Adequate baseline hematological function as assessed by the following laboratory values: * Hemoglobin \> 9 g/dl * Platelets \> 100,000/mm3 * WBC \> 3,000/mm3 * Absolute Neutrophil Count \> 1,500/mm3 Exclusion Criteria: * Coagulation disorders and/or a history of thromboembolic complications, including known hypersensitivity to citrate: e.g., abnormal platelet count, prothrombin time and partial activated thromboplastin time and with a history of deep vein thrombus or pulmonary embolism * Patients with known immunodeficiency virus (HIV)